logoTry Persana

Vir Biotechnology, Inc. - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Vir Biotechnology, Inc. including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Vir Biotechnology, Inc. company logo

Powering the Immune System to Transform Lives

Vir Biotechnology, Inc. leverages the potential of the immune system to develop innovative treatments for serious infectious diseases and cancer. They focus on tailored therapies that can address significant health challenges.

HeadquartersSan Francisco, California, United States
Team size501-1,000
Founded2016

What is Vir Biotechnology, Inc.? - Company Overview & Details

Vir Biotechnology, Inc. is Vir Biotechnology, Inc. leverages the potential of the immune system to develop innovative treatments for serious infectious diseases and cancer. They focus on tailored therapies that can address significant health challenges. Founded in 2016, the company is headquartered in San Francisco, California, United States.

Who Founded Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. was founded by George Scangos.

Who are the Key Executives at Vir Biotechnology, Inc.? - Leadership Team

Vir Biotechnology, Inc. is led by experienced executives in key positions:

Vir Biotechnology, Inc. Company Details & Key Information

Where is Vir Biotechnology, Inc. located?

Vir Biotechnology, Inc. is headquartered in San Francisco, California, United States.

How many employees does Vir Biotechnology, Inc. have?

Vir Biotechnology, Inc. has 501-1,000 employees.

When was Vir Biotechnology, Inc. founded?

Vir Biotechnology, Inc. was founded in 2016.

How much funding has Vir Biotechnology, Inc. raised?

Vir Biotechnology, Inc. has raised $250 Million across 8 funding rounds. The most recent funding was completed on 2024-11-03.

Funding Overview

Vir Biotechnology has secured significant funding to advance its therapies for infectious diseases and cancer, and focus on their chronic hepatitis programs.

$250 Million
Total Funding Raised
8
Funding Rounds
2024-11-03
Latest Round

Vir Biotechnology, Inc. Funding History

Grant
2023-11-03
$50 Million
Equity Investment
2020-04-01
$250 Million

Who are the key investors in Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. is backed by 2 key investors including GlaxoSmithKline, Biomedical Advanced Research and Development Authority (BARDA). These investors focus on Pharmaceuticals, Vaccines, Infectious Diseases sectors.

Vir Biotechnology, Inc. Investor Overview

2
Key Investors
5
Focus Areas
2
Notable Investments

Complete List of Vir Biotechnology, Inc. Investors

GlaxoSmithKline

A global pharmaceutical company with a focus on developing therapies and vaccines for infectious diseases.

Investment Focus
Pharmaceuticals
Vaccines
Infectious Diseases
Notable Portfolio Companies
VIR-7831
VIR-2218

Biomedical Advanced Research and Development Authority (BARDA)

A U.S. government agency providing funding for medical countermeasures, particularly for public health emergencies.

Investment Focus
Biodefense
Disease Prevention

What sectors do Vir Biotechnology, Inc. investors focus on?

The investors backing Vir Biotechnology, Inc. primarily focus on Pharmaceuticals, Vaccines, Infectious Diseases, Biodefense, Disease Prevention sectors.

Pharmaceuticals
Vaccines
Infectious Diseases
Biodefense
Disease Prevention

Featured Investor: GlaxoSmithKline

GlaxoSmithKline

A global pharmaceutical company with a focus on developing therapies and vaccines for infectious diseases.

Notable Investments: VIR-7831, VIR-2218

What are Vir Biotechnology, Inc.'s future plans?

Vir Biotechnology, Inc. Vir Biotechnology aims to continue advancing their clinical pipeline, particularly focusing on hepatitis B and C treatments, while seeking to expand their presence in oncology.

Vir Biotechnology, Inc. Strategic Outlook

Strategic Focus
Defined
3
Key Challenges
3
Growth Opportunities

What challenges does Vir Biotechnology, Inc. face?

Vir Biotechnology, Inc. has identified 3 key challenges that need to be addressed for continued growth and success.

Key Challenges for Vir Biotechnology, Inc.

1

Regulatory approvals

2

Clinical trial results

3

Market competition

What opportunities does Vir Biotechnology, Inc. have?

Vir Biotechnology, Inc. has identified 3 key opportunities for growth and market expansion.

Growth Opportunities for Vir Biotechnology, Inc.

1

Emerging therapies for chronic diseases

2

Partnerships with larger pharmaceutical firms

3

Increased funding for infectious disease research

Vir Biotechnology, Inc. Strategic Position Summary

Key Focus Areas

Vir Biotechnology, Inc. is addressing 3 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 3 key opportunities for expansion and growth.

What are the latest news about Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. has 2 recent news updates covering key business developments and market activities.

Vir Biotechnology, Inc. News Overview

2
Recent Articles
Active
Media Coverage
2025-08-20
Latest Update

What is Vir Biotechnology, Inc. in the news for?

Vir Biotechnology, Inc. is currently featured in news for Vir Biotechnology launches second pivotal trial for chronic hepatitis delta. and other significant business developments.

Recent News Articles About Vir Biotechnology, Inc.

Article 1
2025-08-20

Vir Biotechnology launches second pivotal trial for chronic hepatitis delta.

Vir Biotechnology has begun enrollment for ECLIPSE 2, a pivotal trial for chronic hepatitis delta, demonstrating its commitment to developing effective treatments.

The Healthcare Technology Report
Read News
Article 2
2025-02-19

Vir Biotechnology Inc. attends event TD Cowen 45th Annual Health Care Conference.

Vir Biotechnology announced participation in the TD Cowen conference, where it engaged in discussions regarding its strategies and developments.

Stock Titan
Read News

Vir Biotechnology, Inc. FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Vir Biotechnology, Inc. including information about founders, CEO, funding history, investors, headquarters location, and company details. 15 frequently asked questions covering key information about the company.

Vir Biotechnology, Inc. Questions & Answers - Company Information

Q1

What is Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. leverages the potential of the immune system to develop innovative treatments for serious infectious diseases and cancer. They focus on tailored therapies that can address significant health challenges.

Q2

Who founded Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. was founded by George Scangos.

Q3

How much funding has Vir Biotechnology, Inc. raised?

Vir Biotechnology, Inc. has raised a total of $$250 Million across 8 funding rounds. The most recent funding was completed on 2024-11-03.

Q4

Who are the investors in Vir Biotechnology, Inc.?

Vir Biotechnology, Inc.'s key investors include GlaxoSmithKline, Biomedical Advanced Research and Development Authority (BARDA).

Q5

Where is Vir Biotechnology, Inc. headquartered?

Vir Biotechnology, Inc. is headquartered in San Francisco, California, United States.

Q6

When was Vir Biotechnology, Inc. founded?

Vir Biotechnology, Inc. was founded in 2016.

Q7

How many employees does Vir Biotechnology, Inc. have?

Vir Biotechnology, Inc. has 501-1,000 employees.

Q8

What was Vir Biotechnology, Inc.'s latest funding round?

Vir Biotechnology, Inc.'s latest funding round was a Grant round of $$50 Million completed on 2023-11-03.

Q9

What does the company do?

Vir Biotechnology is focused on developing innovative therapies to treat and prevent serious infectious diseases and cancers.

Q10

How much funding?

$250 Million

Q11

Latest funding date?

2024-11-03

Q12

Who are the investors?

GlaxoSmithKline Biomedical Advanced Research and Development Authority (BARDA)

Q13

What are the challenges?

Regulatory approvals Clinical trial results Market competition

Q14

What are the opportunities?

Emerging therapies for chronic diseases Partnerships with larger pharmaceutical firms Increased funding for infectious disease research

Q15

Latest news?

Vir Biotechnology has begun enrollment for ECLIPSE 2, a pivotal trial for chronic hepatitis delta, demonstrating its commitment to developing effective treatments. Vir Biotechnology announced participation in the TD Cowen conference, where it engaged in discussions regarding its strategies and developments.

More Information About Vir Biotechnology, Inc.

For additional details about Vir Biotechnology, Inc., including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.